Conference Coverage: ASCO & EHA 2019

Dr. Sagar Lonial discusses data from ASCO and EHA 2019 in transplant-eligible patients providing his thoughts on the key takeaways from the CASSIOPEIA trial. 

Dr. Xavier Leleu discusses new data from ASCO and EHA 2019 in patients with myeloma who are not transplant eligible. He also provides his thoughts on whether daratumumab might replace bortezomib.

Dr. Sagar Lonial discusses new data from ASCO and EHA 2019 in Relapsed-Refractory Myeloma

Dr. Xavier Leleu discusses data from ASCO and EHA 2019 on new agents in myeloma.

Dr. Xavier Leleu discusses Melflufen, a lipophilic peptide-conjugated alkylator

Dr. Xavier Leleu discusses data from ASCO and EHA 2019 in transplant-eligible patients, highlighting the key findings from the CASSIOPEIA trial.

Dr. Sagar Lonial discusses new data presented at ASCO and EHA 2019 in Smoldering Myeloma including an update on the IMWG Risk Stratification model and the ECOG randomized trial of lenalidomide vs. observation both of which have important implications in the treatment of patients.

Dr. Xavier Leleu discusses new data from ASCO and EHA 2019 in refractory myeloma.

Dr. Sagar Lonial discusses new data presented as ASCO and EHA 2019 on Cellular Therapies.

Education Conference Coverage EHA & ASCO 2019